Company intelligence / Profile preview

Histostem

Seoul, South Korea

Ownership: Private
Employees: ~84
Development stage: Other

Overview

Histostem treated more than 500 patients with stem cells and was recognized as a leading company in human umbilical cord blood stem cell research and therapy[2]. The company was among the first to apply stem cell therapy to human patients with notable success in treating Buerger's disease, Type 2 diabetes, liver cirrhosis, paralysis after spinal cord injury, osteoporosis, chronic renal failure, and Alzheimer's disease[1].

Therapeutic areas: NephrologyCardiovascularEndocrinologyNeurologyGastroenterologyOncology
Modalities: Stem cell therapy
Industry: Biotech

Partnerships

Stem Cell Therapy International (merged/intended merger in 2008)[2]

Beyond the preview

Go deeper on Histostem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histostem.

Explore the full profile